The role of innate immunity and microglia in the brain is currently a matter of great debate and controversy. While several studies have provided evidence that they contribute to neurodegeneration in various animal models of brain diseases and traumas, others have shown that their inhibition may in contrast be associated with more damages or less repair. We have recently reported the existence of two different types of microglia, the resident and the newly differentiated microglia that derive from the bone marrow stem cells. Of great interest is the fact that blood-derived microglial cells are associated with amyloid plaques and these cells are able to prevent the formation or eliminate the presence of amyloid deposits in mice that develop the major hallmark of Alzheimer's disease (AD). These newly recruited cells are specifically attracted to the b-amyloid 40/42 isoforms in vivo and they participate in the elimination of these proteins by phagocytosis. This review presents the mechanisms involved in the control of the innate immune response by microglia and the beneficial properties of such a response in brain diseases, such as AD.
Innate immunity and the central nervous system
Host organisms detect the presence of infectious agents by recognizing specific molecular elements that are produced by microorganisms, such as bacteria. 1 These elements are called pathogen-associated molecular patterns (PAMPs) and are recognized by specific cells of the innate immune system in order to mount a rapid response to bacterial infection. The endotoxin lipopolysaccharide (LPS), which is the major component of the outer membrane of Gramnegative bacteria, is one of the most characterized molecules known to stimulate the innate immune system and to induce a strong inflammatory response. 2 An essential element of the innate immune response is the secretion of proinflammatory cytokines, which are produced as a result of a PAMP's recognition by its specific receptor.
The idea that the central nervous system (CNS) is impervious to invading pathogens and circulating immune molecules has been refuted over the last few decades. Indeed, it is now well documented that the innate immune system functions to a great extent in the brain (for an in depth review, see Nguyen et al. 3 ).
Although the blood-brain barrier (BBB) presents an effective barrier against the entry of many blood molecules and invading pathogens in most areas of the CNS, it is clear that molecules of the systemic innate immune system are able to stimulate the immune cells of the brain. There is strong evidence that cells of the brain (e.g., microglia) are capable of synthesizing and releasing proinflammatory cytokines. This is achieved by two viable mechanisms, which are via regions that lack the BBB or by a direct stimulation of the endothelium of brain capillaries. Many researchers have observed that systemic immune challenges often initiate the immune response in the CNS first by activating immune cells that are in or near the circumventricular organs. Once these cells are stimulated, they start producing substantial amounts of cytokines, mainly tumor necrosis factor (TNF)-a, which thereafter bind to its receptors on neighboring immune cells in a paracrine manner. As a result, a wave of cytokine expression is instigated and immune cells across the brain parenchyma are activated and begin synthesizing more immune molecules.
The second mechanism consists of an indirect pathway by which CNS vascular cells are targeted by cytokines found in the blood stream. To this end, systemic cytokines can bind their receptors that are expressed on endothelial cells, resulting in the activation of the enzyme cyclooxygenase-2 (COX-2) and the expression of prostaglandins (PGs). 4 These soluble mediators are then released into the brain parenchyma and can diffuse to stimulate nearby neurons. The principal effect of PG synthesis by brain endothelial cells is fever induction and activation of the hypothalamic-pituitary-adrenal (HPA) axis, which ultimately results in the production of glucocorticoids. 5 It is a well-established fact that glucocorticoids are potent inhibitors of inflammation, and this is actually the most powerful endogenous antiinflammatory mechanism in all vertebrates. 6 On the other hand, COX-2 activation in peripheral systems has proinflammatory properties, since it results in the activation of polymorphonuclear cells and the expression of molecules that stimulate the immune system. Despite the dual nature of COX-2 in peripheral organs, this enzyme plays an overall anti-inflammatory role via the production of PGs, activation of the HPA axis and finally the synthesis of glucocorticoids.
The discovery that the CNS was not isolated from the immune system, and that this organ is able to mount a very strong immune response against invading pathogens opened the door to many possibilities. Since then, the major topic for discussion in this scientific field was whether the innate immune system was beneficial or detrimental for the neural environment. Arguments for both cases are very convincing, since it is well known that cytokines such as TNF-a are potent inducers of apoptosis while they also activate nuclear factor-kB-dependent signaling pathways, which often promote cellular growth and survival. Moreover, cytokines amplify the immune response and they induce the expression of chemokines, which serve to recruit other immune cells to the site of inflammation. This phenomenon can also have both positive and negative effects, because immigrating cells can help to rapidly eliminate the invading pathogens, but they can also be harmful to neurons, oligodendrocytes and other cells of the CNS. It has been demonstrated that some of these cytokines induce or promote neurodegeneration while others exert neuroprotective effects. 3 Some cytokines, like TNF-a and interleukin (IL)-1b, seem to have dual roles, since they can be either neurodegenerative or neuroprotective depending on the circumstances.
It is generally well accepted that TNF-a has detrimental systemic effects such as tissue necrosis, vascular coagulation, high fever and respiratory problems. 7 When neurons are concerned, however, results showing the effects of TNF-a and IL-1b on neurodegeneration in vitro are quite contradictory. Certain studies have shown that addition of TNF-a and IL-1b to cultured neurons does not have neurodegenerative effects. 8 Another report demonstrated that when added individually, these cytokines did not induce the death of neurons, but when administered together, neurodegeneration was observed. 9 In contradiction to these results, Strijbos and Rothwell 10 demonstrated that low concentrations of IL-1b have neuroprotective effects, whereas high concentrations are neurotoxic over a longer term. Westmoreland et al. 11 observed that TNF-a is neurodegenerative while IL-1b is not. These contradictory results may be due to differences in the cytokine concentrations that were administered to the cultured neurons. Moreover, these in vitro results may not necessarily reflect the exact nature of the cytokines in vivo, where neurons are accompanied by many other cell types, such as microglia, astrocytes and oligodendrocytes to name a few. Nonetheless, these results are somewhat indicating that TNF-a and IL-1b may be toxic to neurons.
In this regard, there are also many signs that these cytokines may have an active role in the development of neuronal death and the etiology of neurodegenerative diseases. Indeed, positive correlations have been observed between the degree of neuronal death during bacterial meningitis and the levels of TNF-a, IL-1b and IL-1R2. [12] [13] [14] [15] Moreover, TNF-a concentrations are higher than normal in multiple sclerosis (MS) patients 16 and in Alzheimer's patients, 17 while TNF-a and IL-1b levels are increased in those afflicted by Parkinson's disease. 18 Moreover, TNF-a KO mice are protected against neuronal death in models of Parkinson's disease. 19 It has also been demonstrated that TNF-a mRNA synthesis is increased during ischemia and that microglia were the source of the cytokine production. 20 It has been recently established that, when left unchecked, TNF-a induces neural damages and chronic TNF-a infusion in the brain causes neuronal death by apoptosis. 21 In this paper, the authors reported that IL-1b is also neurotoxic, albeit to a much lesser extent than TNF-a. However, it must be noted that the phenomenon only occurred when the production of the cytokines was unregulated or when high physiological concentrations of the cytokines were chronically administered in the CNS, and this has been supported by another study. 22 Indeed, other reports have shown that these cytokines can be neuroprotective during ischemia or cranial trauma when synthesized within physiological concentrations 23, 24 while their overexpression causes neurodegeneration. 25 Moreover, it has been suggested that TNF-a is neuroprotective when it interacts with TNF-R2, whereas the cytokine induces neurodegeneration when it binds TNF-R1. 26 Evidence that IL-1b may also be neuroprotective has been provided by a study demonstrating that IL-1b can protect retinal ganglion cells following optic nerve transection. 27 In a very elegant study, Arnett et al. 28 have used mice lacking TNF-a and its associated receptors to study a model of demyelination and remyelination. Surprisingly, the lack of TNF-a led to a significant delay in remyelination, which was associated with a reduction in the pool of proliferating oligodendrocyte progenitors followed by a reduction in the number of mature oligodendrocytes. This reparative role for TNF-a in the CNS is mediated via the TNFR2, not TNFR1, indicating that the dual nature of TNF-a in demyelination and remyelination may depend on the receptor type and/or the cellular source of the cytokine. Taken together, these data confirm the notion that certain cytokines have dual roles, either promoting death or survival depending on the circumstances. One must therefore to be careful before designing new strategies to either prevent or increase the production of specific innate immune proteins for treating neurodegenerative and demyelinating disorders.
Indeed, studies performed over the last decade have provided evidence supporting both sides of the story. In general, it seems that TNF-a and IL-1b have neuroprotective effects at low concentrations, whereas they cause neuronal death when they are produced in large quantities. However, most of these studies were performed with cultured neurons, and may not necessarily reflect physiological conditions, where neurons are surrounded by many other types of cells. On the other hand, in vivo studies tend to support the idea that these cytokines are neurotoxic rather than neuroprotective. However, in vivo models generally consist of transgenic animals that either overexpress the cytokines or that lack their receptors. These animal models are not necessarily representative of normal physiological conditions and of an appropriate immune response. Therefore, one cannot reject the possibility that TNF-a and IL-1b may protect neurons during inflammation; this is clearly the case during acute demyelination and remyelination. Nevertheless, these cytokines may certainly have detrimental effects on neurons when their secretion is left uncontrolled, which emphasizes the importance of their self-regulation via the activation of the HPA axis and the production of glucocorticoids.
Recruitment of bone marrow-derived cells in the central nervous system
Microglia, representing approximately 5-10% of the adult brain cell population, are essentially the brain macrophages and are thus the immune cells of the CNS. They can clear unwanted debris in the CNS by phagocytosis and produce many cytokines and hence are part of a very elaborate innate immune system that serves to protect our nervous system from unwanted pathogens. To our knowledge, there are three types of microglia in the CNS: the highly ramified parenchymal microglia, the amoeboid microglia and the perivascular microglia, which are tightly associated with blood vessels. Although a large portion of resident microglial cells have been in the CNS since early stages in development, it has recently become clear that bone marrow stem cells can infiltrate the CNS and give rise to new microglia. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] In general, the reports mentioned show that nearly all of the donor-derived microglia are of a perivascular nature since they are closely associated with blood vessels, which confirms the idea that perivascular microglia are indeed bone marrow-derived cells (BMDCs) and do not result from resident brain cell division. However, one study convincingly reports the presence of a few donor-derived parenchymal microglia in the cerebellum (less than 0.3% of total donorderived cells), 41 whereas another paper shows that the majority of the systemically transplanted cells migrated across the BBB to become parenchymal microglial cells throughout the CNS. 43 It is not clear why there are discrepancies between these two studies, since they both used very similar protocols. Nonetheless, these reports can be taken as direct evidence that BMDCs indeed have the ability to populate the CNS and differentiate into functional parenchymal microglia as well as perivascular microglia. These data have been confirmed by a recent study using both lethal irradiation and parabiosis techniques in mice. 44 Although most (if not all) green fluorescent protein (GFP) cells found in the brains of chimeric mice have a microglial phenotype, the overall contributions of such cells to the brain-resident microglial populations remain quite low (e.g., 0.5-11.5% of resident microglia, 44 ).
Bone marrow-derived cells and neurodegenerative diseases
The fact that cells from the blood can cross the BBB, enter the CNS and establish themselves as fully differentiated microglia could have direct implications for the etiology of many neurodegenerative diseases. Even though BMDCs can enter the brain parenchyma throughout the CNS in normal mice, 43 it seems that they are preferentially attracted to regions afflicted by neurodegeneration or neurological insults. 36, 45, 46 In the case of cerebral ischemia, round donor-derived cells (most likely blood monocytes) enter the brain at the site of injury, and then migrate from the infiltration site and become ramified microglial cells. 36 This is also true in models where the BBB is not compromised, such as in the case of facial nerve axotomy. 36 These findings suggest that blood monocytes infiltrate the brain and later differentiate into ramified microglia, and that they are able to enter the CNS even if the BBB is intact.
The exact mechanisms that mediate monocyte recruitment to the brain parenchyma are still unclear, but molecules of the chemokine family are among the most likely candidates. It is generally well accepted that the primary structure of the various chemokines predicts their roles in recruiting distinct subsets of leukocytes. The CXC chemokines have originally been identified as potent activators and chemoattractants for neutrophils, whereas the CC chemokines are believed to mostly attract monocytes. Monocyte chemoattractant protein-1 (MCP-1) is one of the principal CC chemokines that plays a primary role in the recruitment of inflammatory cells in different tissues during acute and chronic inflammation. This chemokine is rapidly synthesized by endothelial and perivascular cells in response to immune stimuli, which triggers monocyte recruitment and rolling prior to their transmigration. In this regard, MCP-1 has been shown to be expressed in many neuroinflammatory diseases, such as experimental autoimmune encephalomyelitis (EAE), the animal model of MS. 47 Cerebral infiltration of blood immune cells have been implicated in EAE and MS, 48 providing a direct link between MCP-1 and the infiltration of monocytes. In fact, differentiated microglia in the brain parenchyma are believed to be responsible for axonal dysfunctions, a consequence of the destruction of the myelin sheath by these infiltrating phagocytes. Thus, the presence of these cells in the CNS, either in cases of brain trauma 36 or in intact animals, 43 may be critical in the role of the immune system in neurodegenerative and demyelinating diseases.
Cells of the adaptive immune system, such as T lymphocytes, are also thought to play an important role in EAE, MS and possibly in other CNS diseases. In order to activate T lymphocytes, major histocompatibility complex class-II (MHC-II) expression and the presentation of a specific antigen by an antigenpresenting cell (APC) is required. It is known that tissue macrophages express high levels of MHC-II, and are thus good APCs, whereas parenchymal microglia express low levels of this protein, indicating that they are poor APCs. 49, 50 However, it has been shown recently that microglia originating from BMDCs express higher levels of MHC-II than their residential counterparts, 36, 43 which suggests that these infiltrated microglia are good APCs and may thus be able to activate cells of the adaptive immune system. Therefore, microglia of blood origin may contribute to the development of debilitating immune processes in the cerebral environment.
Microglia are also involved in the regulation of neurogenesis. In this regard, irradiation has been shown to block the differentiation of neural stem cells in vivo 51 as well as the generation of new neurons. 51, 52 Moreover, neurogenesis can be boosted by injections of minocycline, a compound that blocks the activation of microglia. 53 Interestingly, resident parenchymal microglia do not seem to be fully differentiated into typical myeloid cells 50 and as mentioned, are poor APCs. 49, 50 On the other hand, newly differentiated donor-derived microglia seem to be fully committed myeloid cells and may thus be more easily activated by environmental cues. Consequently, blood-derived microglia may produce higher levels of proinflammatory cytokines, which could lead to decreased neurogenesis in the brain. 54 Since a significant amount of bone marrow-derived microglia are found in the CNS following irradiation, 43 it is quite possible that infiltrating cells are responsible for the neurogenesis impairment seen following radiation therapy.
Based on these data, one would propose that microglia of bone marrow origin are detrimental to the CNS. The opposite may also be true for many reasons. First of all, these phagocytes may enter damaged regions of the brain in order to clear the cellular debris left by dying cells, and hence help re-establish a functional neuronal environment. Secondly, inflammation may also contribute to restore the myelin sheath. There is a temporal expression of neurotrophic factors that follows the endogenous production of proinflammatory cytokines after cerebral injury, suggesting a role for the inflammatory response in mediating neurotrophism. Indeed, microglial-derived IL-1b is required for the production of ciliary neurotrophic factor and insulin-like growth factor-1 by astrocytes, which promote the repair of the injured CNS. Mutant IL-1b-deficient mice fail to remyelinate properly and they exhibit a profound delay to differentiate their progenitors into mature oligodendrocytes. 55 This suggests that early production of IL-1b by parenchymal microglial cells play an essential role in triggering the release of neurotrophic factors by astrocytes in order to facilitate the remyelination and maturation of precursor cells.
As mentioned earlier, conflicting results also exist in regard to the role of TNF-a in either exacerbating brain damages or ameliorating brain recovery during different pathological situations. Bone marrowderived microglia are known to infiltrate regions suffering from demyelination and remyelination 56 and microglia are responsible for the majority of TNF-a production in the brain in response to immune stimuli. 57 Their presence and activation at demyelination sites would thus be beneficial for the CNS in order to promote remyelination. Consequently, inhibiting specific inflammatory pathways may be suitable during demyelinating episodes, but not during remyelination and repair. It is therefore crucial to determine the effects of anti-inflammatory drugs on both processes and to find the exact window in which these compounds may decrease demyelination and favor remyelination. Of great interest is the observation that microglial activation is necessary for efficient removal of compact amyloid deposits with immunotherapy and inhibition of this process may result in an impaired clinical response to vaccination against b-amyloid. 58 Improving immigration of more efficient myeloid cells would therefore be a powerful and innovative approach to inhibit the progression and the removal of plaques (see below).
It is also important to mention that the regenerative capacity of the human CNS, unlike the peripheral nervous system (PNS), is weak to non-existent. Many factors prevent neurons from regenerating their axons following injury, including several myelin-associated proteins that are inhibitory to axon growth and the lack of trophic support from neighboring cells. 59 After peripheral nerve lesion, macrophages are quickly attracted to the site of injury and rapidly phagocytose both axonal debris and inhibitors of axon growth associated with the degenerating myelin. In contrast to the PNS, phagocytic cells take months to clear degenerating myelin from the injured CNS. 59 Thus, the slow migration of microglia into the injured CNS environment might be responsible in part for the discrepancies between the regenerative capacities of the two nervous systems. In the same line, an increased production of MCP-1 within the injured site leads to the recruitment and stimulation of new microglial cells, which ultimately is more effective at removing myelin-associated axon growth inhibitors. 60 With all these data taken into account, it is tempting to propose that a more efficient recruitment of these cells in injured/diseased regions may help the recovery process and restore homeostasis. Unfortunately, this concept is far from being well accepted and several studies are needed to further understand the role of blood-derived microglia in the CNS.
Innate immunity and Alzheimer's disease
Alzheimer's disease (AD) is the most prevalent cause of dementia in humans. This disease is characterized by the presence of b-amyloid deposits in the parenchyma (also known as amyloid plaques or senile plaques) and in the cerebral vasculature. Though plaque formation is strongly correlated with cognitive impairment, 61, 62 the mechanisms responsible for the loss of neurons in AD remain largely unknown. Our understanding of the development of AD is thus very limited and this prevents the development of efficient therapeutic strategies to treat the disease. b-amyloid can be found in many forms in the CNS, such as soluble non-fibrillar amyloid, diffuse fibrillar peptides or as larger fibrillar aggregates. The question as to whether some or all are directly toxic to neurons has been studied and results indicate that aggregated b-amyloid is neurotoxic whereas the others do not affect neuronal viability of primary rat hippocampal cultures. 63 Many studies have provided evidence that microglial cells are attracted to amyloid deposits both in human samples and in rodent transgenic models that develop this disease. [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] It is therefore important to study the development of these deposits, as well as the effects they have on their cellular environment. The precise role of microglia in AD is still under intensive debate. The two major proposals are that these microglia become activated in the presence of b-amyloid and secrete neurotoxic molecules, and the other is that they have neuroprotective actions by secreting neurotrophic agents and eliminating b-amyloid by phagocytosis.
The idea that an immune reaction in AD is the cause of neurodegeneration comes from many reports demonstrating that amyloid plaques are often surrounded by microglial cells, [64] [65] [66] [67] [68] [69] [70] [71] [72] and the fact that cultured microglial cells react to b-amyloid by producing high levels of inflammatory cytokines, such as IL-1b, TNF-a and IL-6 among others. 75, 76 As discussed earlier, this has been linked to cytokine production and neuronal death in cell cultures. [76] [77] [78] [79] [80] There are multiple b-amyloid isoforms present in the CNS, though it seems that neurotoxic properties observed in vitro are mostly attributed to the bAmyloid 1-42 isoform. 78, 80 Some indicate that microglial activation is induced by aggregated b-amyloid, 81 whereas others report that diffuse forms may also be responsible for the immune response seen in this disease. 82, 83 Regardless, since amyloid plaques are predominantly composed of b-amyloid , 84 this theory to explain neuronal loss in AD patients has gained much support in the field. Much less data have been obtained regarding the reactivity of microglia to b-amyloid in vivo. In fact, due to the in vivo data published to date, microglial cells have often been thought to be unable to penetrate the core of amyloid plaques. [70] [71] [72] The authors of these papers propose that b-amyloid found in senile plaques is actually produced by nearby microglial cells or that these cells have a role in the formation of b-amyloid aggregates. Their main conclusions are based on the following findings: (1) the number of microglial cells associated with senile plaques is correlated with the actual size of the bamyloid deposits, and (2) ultrastructural observations demonstrate the presence of fibrillar b-amyloid within cellular compartments of microglia. In most postmortem studies, results indicate that microglia do not penetrate the core of the plaques and that they do not seem to eliminate the b-amyloid deposits by phagocytosis. [70] [71] [72] These data and the failure to demonstrate that microglial cells are able to phagocytose b-amyloid have led to the assumption that the brain's resident macrophages promote the development of the disease since they produce cytotoxic elements and are unable to clear the b-amyloid deposits.
Moreover, initial clinical trials involving the treatment of patients with non-steroidal anti-inflammatory drugs (NSAIDs) prior to the development of AD have suggested that inhibiting the immune response reduces the chance of developing the disease. [85] [86] [87] [88] Some also argue that NSAIDs have no effect in patients already suspected to have developed AD 89 and that treatment with a COX-2 inhibitor increases the amount of b-amyloid found in the brain. 90 One must note that inhibition of COX-2 in the CNS has proinflammatory properties. 91 This recent report demonstrates that NSAIDs enhance the LPS-induced expression of pro-inflammatory molecules such as IL1b, MCP-1, TLR2 and CD14 in vivo. However, it must be noted that COX-2 activation in the CNS leads to systemic production of glucocorticoids, which are the most potent anti-inflammatory molecules known to date. Glucocorticoids are crucial for the proper control of an immune response, therefore preventing their production by inhibiting COX-2 can lead to a heightened inflammatory response, especially in the CNS. 91 It has also been recently shown that COX-2 inhibition 92 and prostaglandin E 2 receptor ablation 93 increases b-amyloid phagocytosis by microglial cells, although the mechanisms mediating these actions remain unknown. We must therefore be careful in the interpretation of clinical trials involving the use of NSAIDS for the treatment of neurodegenerative disorders such as AD, since it may in fact be an increased immune response or an increased phagocytic activity in the CNS that is responsible for the protective effects of these drugs. Many studies support the idea that microglial cells are beneficial to the diseased brain. Indeed, activated microglia are known to favor the release of many neurotrophic molecules which have clear beneficial properties for CNS elements, including neurons and oligodendrocytes. 3 In this regard, microglia inhibition causes extensive damages in acute models of neurotoxicity, where TNF-a/IL-1b double knockouts have larger nitric oxide-induced neuronal damages compared to their wild-type counterparts. 94 Since microglial cells in these animals are unable to mount a proper innate immune response in this model of neurotoxicity, we propose that microglia are indeed beneficial to the prevention of neuronal death and the re-establishment of a functional neural environment. In addition, a few studies have demonstrated that an immune response in the CNS may be beneficial to the organism since it reduces the amount of amyloid deposition. 73, 95 Malm et al. have clearly demonstrated that LPS treatment reduces b-amyloid deposition in APP/PS1 transgenic Alzheimer mice. The notion that microglial cells are able to phagocytose amyloid deposits has been supported in previous reports. [95] [96] [97] The LPS receptor CD14 seems to be a key component in the recognition of b-amyloid and the induction of phagocytosis by microglial cells. 97 Unfortunately, most of the results supporting microglial phagocytosis of b-amyloid have been obtained from in vitro studies, whereas in vivo data confirming this process have not been provided until recently.
We recently hypothesized that most of the microglial cells found closely associated with amyloid plaques are newly differentiated blood-derived microglial cells and that they serve to slow the progression of AD by removing the b-amyloid found in senile plaques. 98 The animal model we used to test this hypothesis was the APP695/PS1 double mutant mice, where senile plaques usually develop within 6 months of age. We created chimeric mice by irradiating these animals and transplanting GFP-expressing bone marrow cells into their bloodstream. We found that in the early stages of plaque formation, most of the microglial cells associated with b-amyloid deposits were resident cells, whereas in medium to large plaques of 6-month-old animals, a large portion of the surrounding microglia were new infiltrating cells of bone marrow origin. Interestingly, the number of bone marrow-derived microglia decreased slightly at the age of 9 months, a time where the number and size of plaques increases dramatically. The cause of the phenomenon needs to be clarified, though a first possible explanation could be that b-amyloid is no longer recognized as an antigen and blood-derived cells are no longer attracted to the deposits or that prolonged b-amyloid exposure decreases microglial functions such as phagocytosis, 99 although resident microglial cells continue to migrate towards the plaques and maintain cytokine expression. Secondly, it may be that monocyte infiltration across the BBB is less frequent in older animals due to the fact that the immune response weakens with age in AD patients 100 and microglial cells seem to have an age-related loss of function. 101 A final alternative explanation is that infiltration of blood-derived cells could still be occurring, though these cells die by apoptosis once they have incorporated enough b-amyloid by phagocytosis, and that the rate of microglial cell death is higher than the rate of their infiltration from the blood stream.
We also found that only b-amyloid-40/42 were able to cause the infiltration of blood-derived microglia. Moreover, b-amyloid-42 was able to induce the expression of inflammatory genes such as TLR2, IL1b and MCP-1, whereas the 31 and 57 amino-acid bamyloid isoforms did not have an effect. 98 Although b-amyloid induces TNF-a expression in cultured microglial cells, 75 this cytokine transcript was not upregulated in our transgenic animals or after bamyloid injections in wild-type mice. This suggests that the immune response in these animals is not the typical inflammatory response observed in many other models of neurodegeneration or acute neurotoxicity. It therefore seems unlikely that inflammation is the direct cause of neuronal dysfunction in this model of AD. Although the precise role of IL-1b in the development of the disease has not been determined, it is quite likely that this cytokine acts as a signal to induce phagocytosis of b-amyloid by microglial cells. It would thus seem that blood-derived microglia are beneficial to the diseased CNS. Although it has previously been suggested that microglial cells are unable to phagocytose b-amyloid in vivo, 76 our data demonstrate that newly differentiated microglial cells originating from the blood are able to remove bamyloid from extracellular environment, whereas resident microglia are ineffective at b-amyloid phagocytosis. 98 These data and the fact that b-amyloid is often found within lysosomes of bone marrowderived microglia suggest that newly infiltrated microglial cells may indeed be able to clear b-amyloid deposits by phagocytosis. Human brain samples of patients diagnosed with AD are usually obtained from very old subjects, a time where the disease is in its final stages. Our study may thus explain reports of human studies demonstrating a lack of b-amyloid phagocytosis by microglial cells, 76 since we have shown that b-amyloid is mostly phagocytosed by microglia originating from the blood and less often by resident microglial cells and that plaques in the later stages of their development contain many resident microglia, whereas there are fewer of their blood-derived counterparts. It is possible that resident microglia take part in b-amyloid deposition, [70] [71] [72] while bone marrow-derived cells serve to eliminate these deposits. Indeed, amyloid plaques are always accompanied with at least one type of microglial cell. However, many of the smaller plaques were not associated with blood-derived microglia in animals younger than 4-5 months. This suggests that resident microglia are present at the onset of plaque formation and hence may play a role in early plaque formation, whereas blood-derived microglia appear at later stages of the disease and may therefore be attempting to clear the senile plaques. Moreover, the ratio of blood-derived vs resident microglia in contact with amyloid plaques seems to slightly decrease at 9 months of age, coinciding with the time when the most significant increase in amyloid deposition occurs. Finally, inhibition of bone marrow-derived microglia substantially increased the presence of amyloid plaques. 98 
Concluding remarks
It is clear that a better understanding of the role of inflammation in the development of many neurodegenerative diseases is required before we can safely develop therapeutic strategies aimed at preventing neuronal damage. While an exaggerated immune response can certainly be detrimental to the CNS, increasing evidence demonstrates that a controlled inflammatory reaction in the brain can be greatly beneficial to the health and proper function of the CNS. In the case of AD, increasing the infiltration of blood-derived microglial cells seems to be a good therapeutic approach since they are able to eliminate or prevent the formation of b-amyloid deposits. Blood-derived monocytes or their precursors would be an ideal alternative to other cells employed in gene therapy, including neural or embryonic stem cells and fibroblasts, because of their natural capacity to populate the adult nervous system and to adapt to inflammatory conditions. In addition, the self-donation of bone marrow would present the advantage of being safe, widely applicable and ethically acceptable. A timely controlled innate immune response may also limit CNS toxicity by eliminating foreign materials and debris, thus contributing to create an environment that is permissive for regeneration and recovery. It is possible that under certain conditions, the recruitment and activity of microglia would need to be suppressed to avoid extended damage, while in other conditions, promoting the inflammatory response may improve regenerative processes. 3, 6 The conclusion that inflammation and microglial reactivity is detrimental for the brain and postnatal neurogenesis seems over generalized and the use of anti-inflammatory drugs to prevent neurodegenerative diseases seems premature at this point. It would therefore be very important to further establish the role of monocyte infiltration in other neurodegenerative diseases before devising therapies that would prevent their recruitment to the CNS.
